ArticleAging2025
Epigenetic age and accelerated aging phenotypes: a tumor biomarker for predicting colorectal cancer.
Article in Aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- Later-generation epigenetic aging clocks outperform first-generation models in predicting survival in TCGA breast cancer.Clinical epigenetics · 2026Article
- Loss of epigenetic adaptation to a high-fat diet in alpha-synuclein transgenic mice.Frontiers in cellular neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEpigenetic clocks, estimated via DNA methylation (DNAm), reflect individuals' biological aging in multiple tissues and are associated with age-related diseases, but their functional role in colorectal cancer (CRC), an age-associated disease, remains unconclusive. DNAm in tumor tissues exclusively exhibits cancerization with expansion of a stem cell pool, leading to the lowest DNAm age; this raises a question about its cancer predictability. Thus, the DNAm aging marker in pre-diagnostic peripheral blood leukocytes (PBLs) may provide key information on CRC etiology and prevention. We aim to examine pre-diagnostic epigenetic makers for aging in PBLs in association with CRC development and risk modification by lifestyles.
methodsUsing data from a large cohort study of white postmenopausal women, we examined biological aging status in PBLs via three well-established epigenetic clocks-Horvath's, Hannum's and Levine's-and prospectively evaluated CRC development in relation to the aging markers and risk modification by lifestyle factors.
resultsThe epigenetic clocks strongly correlated with chronological age, and older DNAm age and age acceleration were significantly associated with increased risk for CRC. Women with bilateral oophorectomy before natural menopause had substantially higher risk for CRC development when they also had epigenetically accelerated aging phenotypes. Among women who maintained healthy dietary patterns, no apparently higher risk was found in those with accelerated aging compared with those with decelerated aging.
conclusionsOur findings contribute to better understanding of the role of a pre-diagnostic epigenetic aging biomarker and its interplay with lifestyles in CRC carcinogenesis, informing risk stratification strategies for aged individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.